levosulpiride Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Levosulpiride, sold under the brand name Neoprad, is a typical antipsychotic and a prokinetic agent of the benzamide class. It is a selective antagonist of the dopamine D2 receptors on both central and peripheral nervous systems. Levosulpiride is claimed to have mood elevating properties.   Wikipedia

Chemistry

  • SMILES: CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N
  • InChIKey: BGRJTUBHPOOWDU-NSHDSACASA-N
  • Mol. Mass: 341.43
  • ALogP: 0.56
  • ChEMBL Molecule:
    levosulpiride  
More Chemistry

Pharmacology

Alternative names

lesuride | levobren | levopraid | levopride | levosulpirida | levosulpiride | levosulpiridum | l-sulpiride | n-(((s)-1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide | rv-12309 | (-)-sulpiride

Organizations (9)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Anxiety (Phase 2/Phase 3)

Diabetic Retinopathy (Phase 2)

Dyspepsia (Phase 1)

Macular Edema (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue